HK1092790A1 - Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators - Google Patents

Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Info

Publication number
HK1092790A1
HK1092790A1 HK06110546.2A HK06110546A HK1092790A1 HK 1092790 A1 HK1092790 A1 HK 1092790A1 HK 06110546 A HK06110546 A HK 06110546A HK 1092790 A1 HK1092790 A1 HK 1092790A1
Authority
HK
Hong Kong
Prior art keywords
benzthiazole
benzimidazole
benzoxazole derivatives
lta4h modulators
lta4h
Prior art date
Application number
HK06110546.2A
Other languages
English (en)
Inventor
Frank U Axe
Scott D Bembenek
Christopher R Butler
James P Edwards
Anne M Fourie
Cheryl A Grice
Brad M Savall
Kevin L Tays
Jianmei Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1092790A1 publication Critical patent/HK1092790A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK06110546.2A 2003-07-28 2006-09-21 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators HK1092790A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28
PCT/US2004/024309 WO2005012297A1 (en) 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Publications (1)

Publication Number Publication Date
HK1092790A1 true HK1092790A1 (en) 2007-02-16

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06110546.2A HK1092790A1 (en) 2003-07-28 2006-09-21 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
HK06110816A HK1090359A1 (en) 2003-07-28 2006-09-28 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK06110816A HK1090359A1 (en) 2003-07-28 2006-09-28 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Country Status (29)

Country Link
US (2) US20050043378A1 (ru)
EP (2) EP1660492B1 (ru)
JP (2) JP4726238B2 (ru)
KR (2) KR101149379B1 (ru)
CN (2) CN100591679C (ru)
AR (2) AR045729A1 (ru)
AT (2) ATE405562T1 (ru)
AU (2) AU2004261628B2 (ru)
BR (2) BRPI0412345A (ru)
CA (2) CA2534228A1 (ru)
CY (1) CY1108560T1 (ru)
DE (2) DE602004016002D1 (ru)
DK (2) DK1660492T3 (ru)
ES (2) ES2311858T3 (ru)
HK (2) HK1092790A1 (ru)
HR (2) HRP20060039A2 (ru)
IL (1) IL173372A (ru)
MY (1) MY145080A (ru)
NO (2) NO20060771L (ru)
NZ (2) NZ544970A (ru)
PL (2) PL1660492T3 (ru)
PT (2) PT1660491E (ru)
RU (2) RU2359970C2 (ru)
SG (2) SG130192A1 (ru)
SI (2) SI1660491T1 (ru)
TW (2) TWI362383B (ru)
UA (2) UA82888C2 (ru)
WO (2) WO2005012296A1 (ru)
ZA (2) ZA200601720B (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660492B1 (en) * 2003-07-28 2008-08-20 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
CA2603122A1 (en) * 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Phenyl and pyridyl lta4h modulators
JP5154406B2 (ja) 2005-04-13 2013-02-27 アステックス、セラピューティックス、リミテッド 医薬化合物
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
DE602006020049D1 (de) * 2005-09-02 2011-03-24 Hoffmann La Roche Benzoxazol-, oxazolopyridin-, benzothiazol- und thiazolopyridinderivate
NZ566788A (en) * 2005-09-21 2012-10-26 Decode Genetics Ehf Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
WO2007073407A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
US7750012B2 (en) * 2005-12-21 2010-07-06 Decode Genetics Ehf Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation
PT1976828T (pt) * 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
WO2007085357A1 (en) * 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
EP2044020B1 (en) * 2006-06-16 2011-05-04 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7989480B2 (en) * 2006-08-04 2011-08-02 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors for treating inflammation
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
WO2008019284A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044054A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in therapy
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
MX2009009491A (es) * 2007-03-08 2009-09-16 Irm Llc Compuestos y composiciones como moduladores de la actividad del gpr119.
JPWO2008120710A1 (ja) * 2007-03-30 2010-07-15 パナソニック電工株式会社 活動強度計
AR069126A1 (es) * 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
RU2526201C2 (ru) * 2007-11-16 2014-08-20 Эббви Инк. Способ лечения артрита
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
DK2336125T3 (da) * 2008-04-11 2013-04-08 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl- og thioazolopyrazin-2-yloxy-phenyl-aminer som modulatorer af leukotrien-A4-hydrolase
WO2009134754A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazole glycinamides as prolyl hydroxylase inhibitors
KR101727650B1 (ko) * 2009-05-14 2017-04-17 얀센 파마슈티카 엔.브이. 류코트리엔 ａ4 하이드롤라아제의 조절제로서의 2개의 융합된 바이사이클릭 헤테로아릴 부분을 갖는 화합물
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
CA2853455C (en) 2011-10-25 2019-12-03 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
EP2968359B1 (en) 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
JP2016513681A (ja) 2013-03-14 2016-05-16 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
AU2014239567B2 (en) 2013-03-14 2017-12-14 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
AU2014366361B2 (en) * 2013-12-17 2017-04-20 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
PT3307734T (pt) 2015-06-09 2020-02-25 Abbvie Inc Moduladores de recetores nucleares (ror) para o tratamento de doenças inflamatórias e autoimunes
CN117887794A (zh) 2016-12-21 2024-04-16 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
MX2021007967A (es) * 2019-01-11 2021-09-21 Naegis Pharmaceuticals Inc Inhibidores de síntesis de leucotrienos.
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
US20230416202A1 (en) * 2020-11-19 2023-12-28 Telo Therapeutics, Inc. Small Molecule Compounds and Compositions
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
AU3297099A (en) * 1998-02-25 1999-09-15 Genetics Institute Inc. Inhibitors of phospholipase a2
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
EP1660492B1 (en) * 2003-07-28 2008-08-20 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
JP4991693B2 (ja) * 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof

Also Published As

Publication number Publication date
EP1660492B1 (en) 2008-08-20
CY1108560T1 (el) 2014-04-09
NZ544938A (en) 2009-05-31
EP1660491A1 (en) 2006-05-31
ES2311858T3 (es) 2009-02-16
PT1660492E (pt) 2008-11-13
RU2359970C2 (ru) 2009-06-27
RU2006102510A (ru) 2006-07-27
DK1660492T3 (da) 2008-11-03
SG130192A1 (en) 2007-03-20
TWI362383B (en) 2012-04-21
NO20060771L (no) 2006-04-21
SI1660491T1 (sl) 2009-02-28
RU2006102508A (ru) 2006-07-27
BRPI0412345A (pt) 2006-10-03
PL1660491T3 (pl) 2009-01-30
AU2004261610A1 (en) 2005-02-10
WO2005012297A1 (en) 2005-02-10
RU2373204C2 (ru) 2009-11-20
NZ544970A (en) 2009-02-28
HK1090359A1 (en) 2006-12-22
ZA200601720B (en) 2007-11-28
ATE403654T1 (de) 2008-08-15
JP4726238B2 (ja) 2011-07-20
KR101149379B1 (ko) 2012-06-28
MY145080A (en) 2011-12-15
AR045730A1 (es) 2005-11-09
WO2005012297A9 (en) 2007-01-04
PL1660492T3 (pl) 2009-01-30
AU2004261610B2 (en) 2010-05-20
UA82888C2 (en) 2008-05-26
UA87986C2 (ru) 2009-09-10
IL173372A (en) 2010-11-30
KR20060057593A (ko) 2006-05-26
ZA200601716B (en) 2007-05-30
NO20060823L (no) 2006-03-15
SI1660492T1 (sl) 2009-02-28
ES2313079T3 (es) 2009-03-01
EP1660491B1 (en) 2008-08-06
DE602004015620D1 (de) 2008-09-18
KR20060054408A (ko) 2006-05-22
US20050043379A1 (en) 2005-02-24
CA2534228A1 (en) 2005-02-10
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
JP2007500706A (ja) 2007-01-18
BRPI0413072A (pt) 2006-10-03
DE602004016002D1 (de) 2008-10-02
AU2004261628A1 (en) 2005-02-10
HRP20060041A2 (en) 2006-11-30
CN100591679C (zh) 2010-02-24
TW200520756A (en) 2005-07-01
HRP20060039A2 (en) 2006-08-31
AU2004261628B2 (en) 2011-05-12
HRP20060041B1 (hr) 2014-06-06
CN1860117A (zh) 2006-11-08
US20050043378A1 (en) 2005-02-24
DK1660491T3 (da) 2008-11-10
CN1856490A (zh) 2006-11-01
WO2005012296A1 (en) 2005-02-10
TW200523255A (en) 2005-07-16
JP2007500703A (ja) 2007-01-18
EP1660492A1 (en) 2006-05-31
SG129449A1 (en) 2007-02-26
PT1660491E (pt) 2008-10-10
IL173372A0 (en) 2006-06-11
ATE405562T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
IL173372A0 (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
IL232313A0 (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the aforementioned
HK1083831A1 (en) Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
IL172894A0 (en) Indol-6-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
IS8319A (is) N-staðgengnir bensimidasólýl c-kit tálmar
DE60328481D1 (de) Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
IL172891A0 (en) Indol-5-yl-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
DE60335031D1 (de) Befestigter anordnungskörper, verbinder und hydraulikzylindereinheit
SI1626964T1 (sl) Novi benzimidazolni derivati
HK1092877A1 (en) Dye-containing polarizer
AU2003278814A8 (en) Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
IL175137A0 (en) Bace455, an alternative splice variant of the human beta-secretase
IL172750A0 (en) Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
TWI348382B (en) N-acetylglucosamine derivatives, and the use thereof
SI1532141T1 (sl) 2-pirolidin-2-il-(1,3,4)-oksadiazolni derivati in njihova uporaba kot antidepresivi
AU2003285498A1 (en) Benzoxazole, benzthiazole and benzimidazole derivatives useful as heparanase inhibitors
ME01506B (me) MODULATORI INDOLAMIN 2,3-DIOKSIGENAZE l POSTUPCI UPOTREBE ISTIH
IS8446A (is) Staðgengin bensimidasól-, benstríasól- og bensimidasólon-o-glúkósíð
FI20030283A (fi) Sovitinlaite
EE04957B1 (et) Kompositsioon ja selle kasutamine raviva, profülaktilise ja kosmeetilise vahendina
DOP2002000500A (es) Benzamida, heteroarilamida y amidas inversas

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170727